P+P advises Vasopharm on EUR 9.5 million financing round
The biopharmaceutical company vasopharm in Würzburg has successfully completed an additional growth financing round in the amount of EUR 9.5 million.
Co-lead investors in this round are, in particular, HeidelbergCapital Private Equity and EF Investments. In addition, current investors such as Bayern Kapital and Ringtons Holdings have also invested. Creathor Ventures is a new investor specializing in life science companies.
Vasopharm's new medication Ronopterin (VAS203) is in the development phase of its for medicinal therapy for moderately severe to severe traumatic brain injuries (TBI). An approval study with 220 patients has been initiated. Up to now, there has been no treatment with medication for traumatic brain injury patients, although just in the EU alone, 1.6 million people are affected each year and many of these have permanent disabilities.
The current financing should allow the company to complete the CMC scale-up in preparation for the production on a commercial level, before a possible application for marketing approval can be submitted. In addition, the company wants to explore alternative indications that manifest a similar mechanism of action.
P+P Partner Michael Inhester advised vasopharm on all legal matters.